Across the globe, the biosimilars industry has been growing stupendously for the past few years. Increasing healthcare costs and rising aging population are driving the industry that is expected to evolve greatly from its current state. In our latest report, it has been estimated that the global biosimilars market will expand at a CAGR of around 52% during 2010-2015. As the governments and private players around the world are stepping into the industry, there are immense opportunities to cash in on.
According to “HGH Biosimilars Market Forecast to 2015”, human growth hormones (HGH) biosimilars are highly important as they help overcome the growth hormones’ inadequacy in both adults and children. They also have multiple applications in several other diseases, such as the treatment for chronic kidney failure, cachexia, liver disease and short bowel syndrome. At the end of 2010, HGH biosimilars captured around one-fourth of the global biosimilars market. Our report provides a thorough study of the HGH biosimilars, and also tells ‘what is going on’ in the market.
The first-generation biosimilars currently dominate the market, and their second-generation is expected to grow stupendously in the future. Our report analyzes and presents forecasts for the global biosimilars and biologics markets. On studying the overall industry’s performance and key biosimilar products in the market, we found that patent expirations offer a huge potential to new market entrants. We have also looked into the competitive landscape, and elaborated the trends and drivers fueling the market growth. Overall, our extensive research report aims at presenting an objective outlook of the global HGH biosimilars market.
